Oruka Therapeutics Inc. Common Stock vs Principal Financial Group Inc Common Stock — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.85 (market cap $5.08B), while Principal Financial Group Inc Common Stock trades at $107.43 (market cap $22.96B). The key difference: Principal Financial Group Inc Common Stock is far larger — about 4.5× Oruka Therapeutics Inc. Common Stock's market cap, and Principal Financial Group Inc Common Stock pays a 3.13% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Principal Financial Group Inc Common Stock for 6 Days on average.
| ORKA | PFG | |
|---|---|---|
Market Cap | $5.08B | $22.96B |
Volume | 685,276 | 1,305,770 |
Sector | Health | Financials |
52-Week High | $113.08 | $118.51 |
52-Week Low | $26.19 | $78.39 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $4.21B | $22.04B |
Dividend Yield | — | 3.13% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Principal Financial Group (PFG) trades at $107.64, down 0.19% with a bearish technical outlook. The stock shows mixed fundamentals with recent earnings beats but faces valuation concerns at a P/E of 15.33. Recent acquisition of Beam Benefits aims to expand digital capabilities in specialty benefits, while analyst sentiment remains cautious with a 'Hold' consensus rating and $108.33 price target.
PFG presents a balanced risk-reward profile with steady revenue growth and improving profit margins, but faces headwinds from technical weakness and mixed analyst sentiment. The Beam Benefits acquisition provides growth potential in the SMB market, though execution risks and competitive pressures in the multiline insurance sector warrant monitoring for investors seeking exposure to financial services.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →Principal Financial Group provides retirement, insurance, and asset management services. It serves individuals, employers, and institutional clients.
Read more on PFG →